EndometriosisNCT04140175
A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.
An observational study of Endometriosis and Chronic Pelvic Pain, run by AbbVie at 117 sites in United States.
Trial summary
This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early intervention on the disease or its symptoms. Read more about this study
- Who is it for?
- Ages 12 years and older, women only
- Conditions the study is for
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- How many people
- 291 participants
- Where
- 117 sitesUnited States
- Study dates
- 20 Jan 2020to 19 Nov 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study will enroll women of reproductive age (between first onset of menses and before onset of menopause) with a suspected or confirmed diagnosis of endometriosis.
Who may be able to join
- Women of reproductive age (between their first menstrual cycle and before onset of menopause).
- Women who have experienced chronic pelvic pain (CPP) and/or dysmenorrhea (DYS) for at least 6 months prior to enrollment without symptom improvement with non-steroidal anti-inflammatory drugs (NSAIDs) or hormone/medical treatment.
- Women with suspected or confirmed endometriosis (EM) at time of enrollment.
- Women with CPP and/or DYS impacting daily activities as determined by their treating physician.
- Able to read, understand and respond to patient questionnaires.
- Willing to sign a patient authorization and/or informed consent form (ICF) and agree to disclose personal health information.
- NOTE: For pediatric patients, parental/guardian assent/ICF is also required.
Who cannot join
- Women with chronic pelvic pain (CPP) and/or dysmenorrhea(DYS) for reasons other than endometriosis (EM).
- Women who have had a hysterectomy and/or bilateral ovary removal (oophorectomy).
- Women who are pregnant or planning to become pregnant.
- Women currently using assisted reproductive technologies such as in vitro fertilization (IVF).
- Women with a history of, or current malignancy (with or without systemic chemotherapy) with the exception of basal cell carcinoma of the skin.
- Women who are currently participating in an interventional clinical trial.
Trial locations and contacts
117 sites in 1 country.
117 sites in 1 country
United States117 sites
Abington Reproductive Medicine /ID# 216575
Abington, Pennsylvania, 19001-3714
Journey Medical Research Insti /ID# 216077
Alpharetta, Georgia, 30005
MAHEC OB/GYN Specialists /ID# 216973
Asheville, North Carolina, 28803-2868
Agile Clinical Research Trials /ID# 217762
Atlanta, Georgia, 30328-5532
Academia Women's Health /ID# 218075
Atlanta, Georgia, 30328
Emory Saint Joseph's Hospital /ID# 213746
Atlanta, Georgia, 30342-1731
Atlanta Women's Research Inst /ID# 216571
Atlanta, Georgia, 30342
Medisense Inc /ID# 218342
Atlanta, Georgia, 30363
Augusta OB/GYN Specialists LLC /ID# 218076
Augusta, Georgia, 30909-6484
MaineGeneral Obstetrics & Gynecology /ID# 217634
Augusta, Maine, 04330-8160
University of Maryland Med Ctr /ID# 216080
Baltimore, Maryland, 21201
Johns Hopkins University /ID# 217958
Baltimore, Maryland, 21287
Great Lakes Research, Inc. /ID# 215764
Bay City, Michigan, 48602
University of Alabama at Birmingham - Women's and Infant's Center /ID# 216236
Birmingham, Alabama, 35294
Boston Medical Center /ID# 218344
Boston, Massachusetts, 02118
Hanjani PC /ID# 217953
Brockton, Massachusetts, 02301-1168
Circuit Clinical - Buffalo /ID# 217656
Buffalo, New York, 14202
Boston Urogynecology Associates /ID# 216232
Cambridge, Massachusetts, 02138-1040
Women's Health Practice, LLC /ID# 216964
Champaign, Illinois, 61820
Chattanoogas Program in Womens /ID# 218052
Chattanooga, Tennessee, 37403
Chattanooga Medical Research /ID# 217594
Chattanooga, Tennessee, 37404
Northwestern Medicine Fertility and Reproductive Medicine /ID# 217662
Chicago, Illinois, 60611-2987
Univ of Cincinnati Physicians /ID# 217643
Cincinnati, Ohio, 45267-0457
Women's Medical Research Group /ID# 216230
Clearwater, Florida, 33759
University Hospitals Cleveland /ID# 216075
Cleveland, Ohio, 44106
MetroHealth Medical Center /ID# 217169
Cleveland, Ohio, 44109
Paramount Research Solutions - College Park /ID# 217959
College Park, Georgia, 30349-3103
Vista Clinical Research /ID# 213789
Columbia, South Carolina, 29201
Aventiv Research, Inc. /ID# 221293
Columbus, Ohio, 43213
Complete Healthcare for Women /ID# 216961
Columbus, Ohio, 43231
Methodist Dallas Medical Center /ID# 218350
Dallas, Texas, 75203-1201
Wright State Univ, School Med /ID# 216084
Dayton, Ohio, 45324
Atlanta VAMC /ID# 215763
Decatur, Alabama, 30033
The Women's Centre /ID# 213794
Denton, Texas, 76210
Women's Care Clinic - Denver Health Main Campus /ID# 217975
Denver, Colorado, 80204-4532
Physicians Research Options, L /ID# 213799
Draper, Utah, 84020
Carolina Women's Research and Wellness Center /ID# 216962
Durham, North Carolina, 27713
Widewaters Gynecology /ID# 217661
East Syracuse, New York, 13057-3072
Horizon Research Group /ID# 217337
Eunice, Louisiana, 70535
Brown, Pearson, Guepet Gynecology /ID# 215500
Fairhope, Alabama, 36532
NECCR Fall River LLC /ID# 216079
Fall River, Massachusetts, 02720-2972
Women's Health Advantage /ID# 217951
Fort Wayne, Indiana, 46825
Signature Gyn Services /ID# 216354
Fort Worth, Texas, 76104
Willowbend Health and Wellness - Frisco /ID# 217601
Frisco, Texas, 75035
Womens Health Center /ID# 216235
Glen Burnie, Maryland, 21063
University Medical Group /ID# 217954
Greenville, South Carolina, 29605
Advanced Women's Health Institute /ID# 217342
Greenwood Village, Colorado, 80111
Capital Women's Care - Hagerstown /ID# 217984
Hagerstown, Maryland, 21740-6555
Penn State University and Milton S. Hershey Medical Center /ID# 213787
Hershey, Pennsylvania, 17033-2360
UNC Hospitals - Hillsborough /ID# 218343
Hillsborough, North Carolina, 27278-9078
Houston Methodist Hospital /ID# 216967
Houston, Texas, 77030
Leavitt Womens Healthcare /ID# 221355
Idaho Falls, Idaho, 83404-8322
Womens Healthcare Assoc, DBA /ID# 217839
Idaho Falls, Idaho, 83404
University of Mississippi Medi /ID# 217636
Jackson, Mississippi, 39216
Univ Kansas Med Ctr /ID# 216086
Kansas City, Kansas, 66160
GYN Research Institute - Kissimmee /ID# 217979
Kissimmee, Florida, 34741-4986
Altus Research, Inc /ID# 213740
Lake Worth, Florida, 33461
R. Garn Mabey Jr, MD Chartered /ID# 218065
Las Vegas, Nevada, 89128
Virginia Obstetrics & Gynecology /ID# 215797
Leesburg, Virginia, 20176-3465
Olympia Clinical Trials /ID# 216238
Los Angeles, California, 90036-4667
Norton Children's Gynecology /ID# 215671
Louisville, Kentucky, 40207-4700
South Florida Wellness & Clinic /ID# 217637
Margate, Florida, 33063
WellStar Kennestone Women's Health Clinic /ID# 216983
Marietta, Georgia, 30060-1134
Cooper University Hospital/Sheridan Pavilion /ID# 218066
Marlton, New Jersey, 08053-3464
Advanced Clinical Research /ID# 218346
Meridian, Idaho, 83642
University of Miami /ID# 217952
Miami, Florida, 33136
Palmetto Professional Research /ID# 218051
Miami, Florida, 33186-1309
Women's Health Alliance of Mobile /ID# 213719
Mobile, Alabama, 36604-1410
Mobile, Ob-Gyn, P.C. /ID# 217761
Mobile, Alabama, 36608
West Virginia University /ID# 217664
Morgantown, West Virginia, 26506
Venus Gynecology, LLC /ID# 213790
Myrtle Beach, South Carolina, 29572
Paramount Research Solutions - Nashville /ID# 217341
Nashville, Tennessee, 37203-2012
Urology Associates PC - Nashville /ID# 218139
Nashville, Tennessee, 37209-4035
Jersey Shore University Medical Center /ID# 216488
Neptune City, New Jersey, 07753-4859
Eastern Carolina Women's Centr /ID# 217335
New Bern, North Carolina, 28562
Rutgers Robert Wood Johnson /ID# 216972
New Brunswick, New Jersey, 08901
Yale University /ID# 217978
New Haven, Connecticut, 06510
Ochsner Baptist Medical Centre /ID# 215762
New Orleans, Louisiana, 70115
Manhattan Medical Research /ID# 217950
New York, New York, 10016-6023
Mount Sinai Medical Center - NY /ID# 216208
New York, New York, 10029-6501
Christiana Care Health Service /ID# 218097
Newark, Delaware, 19713
Reproductive Assoc of Delaware /ID# 216082
Newark, Delaware, 19713
Affinity Clinical Research /ID# 218203
Oak Brook, Illinois, 60523
CHI Health /ID# 216074
Omaha, Nebraska, 68131
A Premier Clinical Research of Florida, LLC /ID# 217949
Orange City, Florida, 32763-2833
Camran Nezhat Institute /ID# 216083
Palo Alto, California, 94304-1805
The Advanced Gynecologic Surgery Institute - Park Ridge /ID# 217635
Park Ridge, Illinois, 60068
Suffolk Obstetrics and Gyneco /ID# 213781
Port Jefferson, New York, 11777
M3 Wake Research Inc. /ID# 217167
Raleigh, North Carolina, 27612-8106
Virginia Women's Health Associates - Reston /ID# 217990
Reston, Virginia, 20190-3215
Clinical Research Partners, LLC /ID# 216355
Richmond, Virginia, 23220-4459
Granger Medical Clin-Riverton /ID# 218086
Riverton, Utah, 84065
Central Michigan University Health /ID# 216237
Saginaw, Michigan, 48602-5303
Saginaw Valley Med Res Group /ID# 217763
Saginaw, Michigan, 48604
Univ Texas HSC San Antonio /ID# 218070
San Antonio, Texas, 78229
Infertility, Gynecology & Obst /ID# 213734
San Diego, California, 92121
West Coast Medical Research, I /ID# 217638
San Diego, California, 92123-3357
Physician Care Clin. Res., LLC /ID# 216570
Sarasota, Florida, 34239
Seattle Reproductive Medicine /ID# 213801
Seattle, Washington, 98109
Womens & Family Care, LLC dba /ID# 216569
Shawnee Mission, Kansas, 66218
LSUHSC - Shreveport /ID# 216229
Shreveport, Louisiana, 71103
Omni Fertility and Laser Insti /ID# 217764
Shreveport, Louisiana, 71118
Saint Louis University School of Medicine /ID# 217633
St Louis, Missouri, 63104
Stamford Hospital /ID# 216975
Stamford, Connecticut, 06902
Richmond OB/GYN Associates PC /ID# 217642
Staten Island, New York, 10306
Island Reproductive Services - Staten Island /ID# 218202
Staten Island, New York, 10309-2622
Palmetto Clinical Research /ID# 216076
Summerville, South Carolina, 29485-7539
Women's Health Partners - Summerville /ID# 217339
Summerville, South Carolina, 29485-8154
SUNY Upstate Medical University - Downtown /ID# 217596
Syracuse, New York, 13210
GCP Clinical Research, LLC /ID# 218861
Tampa, Florida, 33609-4044
University of South Florida /ID# 217606
Tampa, Florida, 33612
Stedman Clinical Trials /ID# 217595
Tampa, Florida, 33613
Visions Clinical Research-Tucs /ID# 216352
Tucson, Arizona, 85712
The Chronic Pelvic Pain Center of Northern VA /ID# 217630
Vienna, Virginia, 22182-2665
UnityPoint Clinic OB/GYN - Waterloo /ID# 216087
Waterloo, Iowa, 50703-1901
Cypress Medical Research Ctr /ID# 218054
Wichita, Kansas, 67226
UMass Memorial Health Care /ID# 217608
Worcester, Massachusetts, 01605-2903
About this study
Official title: A Multicenter, Observational Cohort Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Attributable to Suspected or Confirmed Endometriosis
This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early intervention on the disease or its symptoms. Length of treatment is dependent on standard of care treatment provided and all study information will be collected during routine standard of care visits.
- Conditions
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- Keywords
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- Medical subject headings
- Endometriosis, Dysmenorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Women with suspected or confirmed endometriosis | Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants using specific medications for the treatment of chronic pelvic pain (CPP) and/or dysmenorrhea (DYS)
Data regarding medication use for CPP and/or DYS will be collected from participant medical records, health care provider questionnaires, and participant completed questionnaires.
Measured: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS
Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS at any point from onset of CPP and/or DYS and study completion.
Measured: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Number of surgical interventions for the treatment of CPP and/or DYS
Number of surgical interventions for the treatment of CPP and/or DYS.
Measured: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Percentage of participants undergoing hysterectomy
Percentage of participants undergoing hysterectomy during study enrollment.
Measured: From study enrollment (Week 0) to up to 4 years.
Percentage of participants undergoing infertility treatment
Percentage of participants undergoing infertility treatments during study enrollment.
Measured: From study enrollment (Week 0) to up to 4 years.
Percentage of participants undergoing surgery
Percentage of participants undergoing surgery as treatment for CPP and/or DYS.
Measured: From study enrollment (Week 0) to up to 4 years.
Percentage of participants with complications associated with surgery
Percentage of participants with complications associated with surgery.
Measured: From study enrollment (Week 0) to up to 4 years.
Percentage of participants receiving specific treatment sequences for the treatment of CPP and/or DYS
Treatment sequences will be identified from the data. Treatment switching, add-on treatment, and discontinuations (including reasons) will be collected wherever possible.
Measured: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2019
- Study start20 Jan 2020
- Primary completion19 Nov 2020
- Study completion19 Nov 2020
Why it stopped: Strategic considerations
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 291 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04140175
- Sponsor's protocol ID
- P16-836
- Status last verified
- Nov 2021
- First submitted
- 24 Oct 2019
- Last updated
- 22 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Observational Cohort Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Attributable to Suspected or Confirmed Endometriosis
- ClinicalTrials.gov ID
- NCT04140175
- Acronym / sponsor ID
- P16-836
- Conditions
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- Keywords
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Strategic considerations
- Enrolment
- 291 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 20 Jan 2020 (actual)
- Primary completion
- 19 Nov 2020 (actual)
- Study completion
- 19 Nov 2020 (actual)
- First posted
- 25 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early intervention on the disease or its symptoms. Length of treatment is dependent on standard of care treatment provided and all study information will be collected during routine standard of care visits.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Women with suspected or confirmed endometriosis | – | –Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions. |
Who may qualify
- Ages
- 12 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study will enroll women of reproductive age (between first onset of menses and before onset of menopause) with a suspected or confirmed diagnosis of endometriosis.
Key inclusion criteria (7 listed)
- Women of reproductive age (between their first menstrual cycle and before onset of menopause).
- Women who have experienced chronic pelvic pain (CPP) and/or dysmenorrhea (DYS) for at least 6 months prior to enrollment without symptom improvement with non-steroidal anti-inflammatory drugs (NSAIDs) or hormone/medical treatment.
- Women with suspected or confirmed endometriosis (EM) at time of enrollment.
- Women with CPP and/or DYS impacting daily activities as determined by their treating physician.
- Able to read, understand and respond to patient questionnaires.
Key exclusion criteria (6 listed)
- Women with chronic pelvic pain (CPP) and/or dysmenorrhea(DYS) for reasons other than endometriosis (EM).
- Women who have had a hysterectomy and/or bilateral ovary removal (oophorectomy).
- Women who are pregnant or planning to become pregnant.
- Women currently using assisted reproductive technologies such as in vitro fertilization (IVF).
- Women with a history of, or current malignancy (with or without systemic chemotherapy) with the exception of basal cell carcinoma of the skin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of participants using specific medications for the treatment of chronic pelvic pain (CPP) and/or dysmenorrhea (DYS)
Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Data regarding medication use for CPP and/or DYS will be collected from participant medical records, health care provider questionnaires, and participant completed questionnaires.
Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS
Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS at any point from onset of CPP and/or DYS and study completion.
Number of surgical interventions for the treatment of CPP and/or DYS
Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Number of surgical interventions for the treatment of CPP and/or DYS.
Percentage of participants undergoing hysterectomy
Time frame: From study enrollment (Week 0) to up to 4 years.
Percentage of participants undergoing hysterectomy during study enrollment.
Percentage of participants undergoing infertility treatment
Time frame: From study enrollment (Week 0) to up to 4 years.
Percentage of participants undergoing infertility treatments during study enrollment.
Percentage of participants undergoing surgery
Time frame: From study enrollment (Week 0) to up to 4 years.
Percentage of participants undergoing surgery as treatment for CPP and/or DYS.
Percentage of participants with complications associated with surgery
Time frame: From study enrollment (Week 0) to up to 4 years.
Percentage of participants with complications associated with surgery.
Percentage of participants receiving specific treatment sequences for the treatment of CPP and/or DYS
Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.
Treatment sequences will be identified from the data. Treatment switching, add-on treatment, and discontinuations (including reasons) will be collected wherever possible.
Results and safety
The study was stopped early (reason given: Strategic considerations). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Nov 2021.
- clinical study report synopsisLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
117 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis and Chronic Pelvic Pain, run by AbbVie at 117 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 117 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Strategic considerations). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants using specific medications for the treatment of chronic pelvic pain (CPP) and/or dysmenorrhea (DYS) (time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2021.